These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28939376)

  • 1. In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye.
    Peynshaert K; Devoldere J; De Smedt SC; Remaut K
    Adv Drug Deliv Rev; 2018 Feb; 126():44-57. PubMed ID: 28939376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug delivery to the posterior segment of the eye.
    Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
    Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming ocular drug delivery barriers through the use of physical forces.
    Huang D; Chen YS; Rupenthal ID
    Adv Drug Deliv Rev; 2018 Feb; 126():96-112. PubMed ID: 28916492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell penetrating peptides in ocular drug delivery: State of the art.
    Pescina S; Ostacolo C; Gomez-Monterrey IM; Sala M; Bertamino A; Sonvico F; Padula C; Santi P; Bianchera A; Nicoli S
    J Control Release; 2018 Aug; 284():84-102. PubMed ID: 29913221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of lipid nanoparticles to ocular drug delivery.
    Battaglia L; Serpe L; Foglietta F; Muntoni E; Gallarate M; Del Pozo Rodriguez A; Solinis MA
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1743-1757. PubMed ID: 27291069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
    Fangueiro JF; Veiga F; Silva AM; Souto EB
    Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Nanotherapies for the Posterior Segment of the Eye: An Integrative Review on Recent Advancements and Challenges.
    Gogoi NR; Marbaniang D; Pal P; Ray S; Mazumder B
    Pharm Nanotechnol; 2022 Nov; 10(4):268-278. PubMed ID: 35946098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modern drug delivery systems for targeting the posterior segment of the eye.
    Peptu CA; Popa M; Savin C; Popa RF; Ochiuz L
    Curr Pharm Des; 2015; 21(42):6055-69. PubMed ID: 26503152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular Drug Delivery.
    Yavuz B; Kompella UB
    Handb Exp Pharmacol; 2017; 242():57-93. PubMed ID: 27783270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotherapy for posterior eye diseases.
    Kaur IP; Kakkar S
    J Control Release; 2014 Nov; 193():100-12. PubMed ID: 24862316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery.
    Bhattacharjee A; Das PJ; Adhikari P; Marbaniang D; Pal P; Ray S; Mazumder B
    Eur J Ophthalmol; 2019 Jan; 29(1):113-126. PubMed ID: 29756507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of therapeutics for deep-seated ocular conditions - status quo.
    Nguyen H; Eng S; Ngo T; Dass CR
    J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
    Wang R; Gao Y; Liu A; Zhai G
    J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy.
    Swetledge S; Jung JP; Carter R; Sabliov C
    J Nanobiotechnology; 2021 Jan; 19(1):10. PubMed ID: 33413421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent perspectives in ocular drug delivery.
    Gaudana R; Jwala J; Boddu SH; Mitra AK
    Pharm Res; 2009 May; 26(5):1197-216. PubMed ID: 18758924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal drug delivery in retinal disease: are we out of our depth?
    Thakur SS; Barnett NL; Donaldson MJ; Parekh HS
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1575-90. PubMed ID: 24931577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in ocular drug delivery.
    Rawas-Qalaji M; Williams CA
    Curr Eye Res; 2012 May; 37(5):345-56. PubMed ID: 22510004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery to the posterior segment of the eye.
    Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
    Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.